Brief: Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
10/11/2023 13:55
Nov 10 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* HEPION PHARMACEUTICALS SCHEDULES CONFERENCE CALL TO REVIEW
ADDITIONAL EFFICACY DATA FROM PHASE 2 ‘ALTITUDE-NASH’ LIVER
FUNCTION TRIAL OF RENCOFILSTAT
* HEPION PHARMACEUTICALS - EXPECTS TO RELEASE ADDITIONAL
EFFICACY
DATA FROM PHASE 2 ALTITUDE-NASH CLINICAL TRIAL OF LEAD DRUG,
RENCOFILSTAT, ON NOV 13
Source text for Eikon: ID:nGNX2kjSWK
Further company coverage: HEPA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement